Immunogenicity of a recombinant yeast-derived hepatitis B vaccine (Engerix B) in children

N Z Med J. 1988 Apr 13;101(843):162-4.

Abstract

Eighty-one children seronegative for markers of hepatitis B virus infection aged 0-10 years received 10 micrograms of a yeast-based hepatitis B vaccine (Engerix B) at 0, 1, and 6 months. Eighty subjects responded with a geometric mean titre of 7640 IU/L one month after the third dose. All seroconverters produced high level of antibodies regardless of age, race, or sex. It is concluded that Engerix B used in the dose and schedule described is highly immunogenic.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens / immunology*
  • Child
  • Child, Preschool
  • Female
  • Hepatitis B Antibodies / biosynthesis
  • Hepatitis B Surface Antigens / analysis
  • Hepatitis B Vaccines
  • Humans
  • Immunoenzyme Techniques
  • Infant
  • Male
  • Radioimmunoassay
  • Vaccines, Synthetic / adverse effects
  • Vaccines, Synthetic / immunology*
  • Viral Hepatitis Vaccines / adverse effects
  • Viral Hepatitis Vaccines / immunology*

Substances

  • Antigens
  • Hepatitis B Antibodies
  • Hepatitis B Surface Antigens
  • Hepatitis B Vaccines
  • Vaccines, Synthetic
  • Viral Hepatitis Vaccines